Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Opus Genetics, Inc.NASDAQ: IRD
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 184.6% from a year ago
Other current assets stood at $3.93M at the end of Q1 FY2026, up 184.6% from a year earlier and up 119.6% from the prior quarter. Over 3 fiscal years it compounded at +181.7% a year.
Context
- Other current assets amounted to 5.9% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +184.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.79M USD
- Year-over-year change
- +247.2%
- 4-year CAGR
- +124.0%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.79M | +247.2% |
| FY2024 | 2024-12-31 | 515K | +404.9% |
| FY2023 | 2023-12-31 | 102K | +27.5% |
| FY2022 | 2022-12-31 | 80K | +12.7% |
| FY2021 | 2021-12-31 | 71K | — |
Other Current Assets vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 other current assets of $3.93M is the 3rd highest of the 10 companies compared; the peer median is $2.04M.
- Its year-over-year change of +184.6% is the highest of 8, against a peer median of -27.7%.
- Other current assets amounts to 5.9% of total assets for IRD, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $112.36M | -0.8% | +136.9% | 56.1% | |
| Mar 2026 | $8.57M | -29.2% | — | 3.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $3.93M | +184.6% | +181.7% | 5.9% |
| Mar 2026 | $3.57M | -27.7% | +43.1% | 2.7% | |
| Mar 2026 | $2.59M | -17.1% | -3.4% | 1.0% | |
| Mar 2026 | $2.04M | -15.9% | — | 1.1% | |
| Mar 2026 | $1.77M | -37.8% | -37.7% | 1.5% | |
| Mar 2026 | $1.03M | — | — | 2.8% | |
| Mar 2026 | $367.51K | -47.7% | +36.9% | 1.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IRD) | $2.04M | -27.7% | +36.9% | 1.5% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.